October 2026
1. KARAKULAK T, Moch H, von Mering C, Kahraman A, et al
   Switches in alternatively spliced isoforms impact protein and drug interactions in melanoma, ovarian cancer, and acute myeloid leukemia.
   Br J Cancer. 2026 Oct 3. doi: 10.1038/s41416-026-03638.
   

   >> Share

   
   
2. POON KS, Koay ES
   CBL in stage II melanoma: considerations of variant interpretation for driver gene designation.
   Br J Cancer. 2026 Oct 1. doi: 10.1038/s41416-026-03629.
   

   >> Share

   
   September 2026
3. HAN J, Gao X, Jiang W
   Methodological considerations in defining CBL as a prognostic biomarker in stage II melanoma.
   Br J Cancer. 2026 Sep 21. doi: 10.1038/s41416-026-03628.
   

   >> Share

   
   
4. PIRES L, Calcada C, Cerqueira-Rodrigues B, Fan Y, et al
   Photodynamic immune stimulation eradicates primary pigmented melanoma and induces long-lasting anti-tumor immunity.
   Br J Cancer. 2026 Sep 15. doi: 10.1038/s41416-026-03585.
   

   >> Share

   
   July 2026
5. CAVILLON A, Borget I, Robert C, Chevret S, et al
   The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.
   Br J Cancer. 2026 Jul 3. doi: 10.1038/s41416-026-03528.
   

   >> Share

   
   June 2026
6. D'MELLOW M, Wang H, Palmer JM, Hemminki K, et al
   GWAS meta-analysis provides new insights into uveal melanoma risk.
   Br J Cancer. 2026 Jun 16. doi: 10.1038/s41416-026-03499.
   

   >> Share

   
   
7. BREEZE SO, Heaton MJ, Snelling AP, Garioch JJ, et al
   Implications of wait times for sentinel node biopsy on melanoma disease progression, micrometastatic tumour burden and survival outcomes in the modern treatment era.
   Br J Cancer. 2026 Jun 16. doi: 10.1038/s41416-026-03497.
   

   >> Share

   
   
8. CHIN JH, Kim D, Lee HS, Jeon S, et al
   Adjuvant radiotherapy and skin cancer risk in breast cancer survivors: a nationwide cohort study in Korea.
   Br J Cancer. 2026 Jun 12. doi: 10.1038/s41416-026-03485.
   

   >> Share

   
   
9. HERCENT A, Mary M, Tchernitchko D
   Comment on "Risk of malignant melanoma and colorectal cancer in Birt-Hogg-Dube syndrome-a matched cohort study" by Skarin Nordenvall et al.
   Br J Cancer. 2026 Jun 9. doi: 10.1038/s41416-026-03500.
   

   >> Share

   
   April 2026
10. ESTAY R, Cortes A, Muller B, Tempio F, et al
    Phase I trial of a heat-conditioned tumor lysate vaccine (TRIMELVax) in anti-PD-1 refractory melanoma: safety and immunological aspects (NCT06556004).
    Br J Cancer. 2026 Apr 30. doi: 10.1038/s41416-026-03459.
    

    >> Share

    
    
11. REA B, Salehi M, Maiter A, Ochieng L, et al
    Hepatic metastasis surveillance in uveal melanoma: a retrospective cohort study from a UK tertiary centre (2006-2022).
    Br J Cancer. 2026 Apr 16. doi: 10.1038/s41416-026-03445.
    

    >> Share

    
    
12. LINDNER ES, Admard J, Demidov G, Armeanu-Ebinger S, et al
    Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.
    Br J Cancer. 2026 Apr 9. doi: 10.1038/s41416-026-03394.
    

    >> Share

    
    February 2026
13. WOODFORD R, Lorigan P, Oudit D, Abdulgawad A, et al
    Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?
    Br J Cancer. 2026 Feb 18. doi: 10.1038/s41416-026-03350.
    

    >> Share

    
    December 2025
14. BERTHOD G, Cisarovsky C, Petrova T, Decosterd LA, et al
    Sorafenib plus selective internal radiotherapy with (90)Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial.
    Br J Cancer. 2025 Dec 11. doi: 10.1038/s41416-025-03279.
    

    >> Share

    
    November 2025
15. GAETA A, Nuvoli L, Doccioli C, Caini S, et al
    Sex and gender influence on adverse events for melanoma patients: a comprehensive review and meta-analysis.
    Br J Cancer. 2025 Nov 22. doi: 10.1038/s41416-025-03266.
    

    >> Share

    
    
16. SKARIN NORDENVALL A, Persson F, Martling A, Nordenskjold M, et al
    Risk of malignant melanoma and colorectal cancer in Birt-Hogg-Dube syndrome - a matched cohort study.
    Br J Cancer. 2025 Nov 5. doi: 10.1038/s41416-025-03258.
    

    >> Share

    
    September 2025
17. VAN DAM S, Krijgsman D, Kucukkose E, Verdonschot MEL, et al
    Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment.
    Br J Cancer. 2025 Sep 2. doi: 10.1038/s41416-025-03137.
    

    >> Share

    
    July 2025
18. SIMBA H, McCormack V, Bilaba J, Mmbaga BT, et al
    Non-melanoma skin cancer and HPV in persons with albinism: a call for research investment.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03107.
    

    >> Share

    
    May 2025
19. NORINGRIIS IM, Donia M, Madsen K, Schmidt H, et al
    Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.
    Br J Cancer. 2025 May 26. doi: 10.1038/s41416-025-03048.
    

    >> Share

    
    April 2025
20. VAN DIJK EJ, Nienhuis HH, van den Eertwegh AJM, Boers-Sonderen MJ, et al
    Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.
    Br J Cancer. 2025 Apr 29. doi: 10.1038/s41416-025-03027.
    

    >> Share

    
    
21. BROCHE C, Um K, Vilgrain I, Mouret S, et al
    Soluble VE-cadherin as a biomarker of response to immunotherapy by anti-PD1 in metastatic melanoma.
    Br J Cancer. 2025 Apr 18. doi: 10.1038/s41416-025-03026.
    

    >> Share

    
    
22. BLOEM M, de Meza MM, van den Eertwegh AJM, Aarts MJB, et al
    Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.
    Br J Cancer. 2025 Apr 15. doi: 10.1038/s41416-025-03021.
    

    >> Share

    
    November 2024
23. MHAIDAT NM, Zhang XD, Allen J, Avery-Kiejda KA, et al
    Editorial Expression of Concern: Temozolomide induces senescence but not apoptosis in human melanoma cells.
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02907.
    

    >> Share

    
    October 2024
24. CHATTOPADHYAY C, Roszik J, Bhattacharya R, Alauddin M, et al
    Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma.
    Br J Cancer. 2024 Oct 11. doi: 10.1038/s41416-024-02866.
    

    >> Share

    
    
25. PUDJIHARTONO M, Pudjihartono N, O'Sullivan JM, Schierding W, et al
    Melanoma-specific mutation hotspots in distal, non-coding, promoter-interacting regions implicate novel candidate driver genes.
    Br J Cancer. 2024 Oct 4. doi: 10.1038/s41416-024-02870.
    

    >> Share

    
    August 2024
26. ORAIOPOULOU ME, Couturier DL, Bunce EV, Cannell IG, et al
    The in vitro dynamics of pseudo-vascular network formation.
    Br J Cancer. 2024;131:457-467.
    

    >> Share

    
    
27. MERRICK S, Rush HL, Daniels S, Fielding A, et al
    Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition.
    Br J Cancer. 2024;131:515-523.
    

    >> Share

    
    June 2024
28. SCHORGHOFER D, Vock L, Mirea MA, Eckel O, et al
    Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation.
    Br J Cancer. 2024 Jun 20. doi: 10.1038/s41416-024-02758.
    

    >> Share

    
    February 2024
29. ZAKKAK N, Barclay ME, Swann R, McPhail S, et al
    The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit.
    Br J Cancer. 2024;130:297-307.
    

    >> Share

    
    December 2023
30. WANG S, Riedstra CP, Zhang Y, Anandh S, et al
    PTEN-restoration abrogates brain colonisation and perivascular niche invasion by melanoma cells.
    Br J Cancer. 2023 Dec 26. doi: 10.1038/s41416-023-02530.
    

    >> Share

    
    
31. MAVOR ME, Hanna TP, Asai Y, Langley H, et al
    Factors associated with the melanoma diagnostic interval in Ontario, Canada: a population-based study.
    Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02518.
    

    >> Share

    
    October 2023
32. LIU M, Dong Q, Chen B, Liu K, et al
    Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells.
    Br J Cancer. 2023;129:1339-1349.
    

    >> Share

    
    
33. DONINI C, Galvagno F, Rotolo R, Massa A, et al
    PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade.
    Br J Cancer. 2023;129:1409-1416.
    

    >> Share

    
    July 2023
34. MARIANI P, Torossian N, van Laere S, Vermeulen P, et al
    Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.
    Br J Cancer. 2023 Jul 13. doi: 10.1038/s41416-023-02331.
    

    >> Share

    
    March 2023
35. RODRIGUES A, Cosman R, Joshua AM
    Correction To: LXS196 for Metastatic Uveal Melanoma - finally some progress.
    Br J Cancer. 2023 Mar 28. doi: 10.1038/s41416-023-02231.
    

    >> Share

    
    
36. RODRIGUES A, Cosman R, Joshua AM
    LXS196 for Metastatic Uveal Melanoma - finally some progress.
    Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02199.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share